Nipah was first identified about 25 years ago in Malaysia and has led to outbreaks in Bangladesh, India and Singapore. The first participants in the Oxford trial received doses of the vaccine over the last week. The shot is based on the same technology as the one used in AstraZeneca and Serum Institute of India's COVID-19 shots.
The first participants in the Oxford trial received doses of the vaccine over the last week. The shot is based on the same technology as the one used in AstraZeneca (AZN.L) and Serum Institute of India's Covid-19 shots.
Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah and be part of a vital initiative.
Oxford Vaccine Group, part of the University’s Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAdOx1 NipahB vaccine, targeting…